Dojolvi (TriHEPtanoin) Patent Expiration, LOE Window & CMS Spending
Dojolvi (TriHEPtanoin) by Ultragenyx Pharmaceutical: FDA Orange Book LOE 2034-11-14, 0 AB generics, $25.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ultragenyx Pharmaceutical |
| FDA Application & Pathway | N213687 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-11-14 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $25.4M |
| 2024 Medicare Part D Spend | $2.9M |
| 2024 Medicaid Spend | $22.5M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.